FDA Boots 15 Forgotten Drugs from Approval List Cleanly
Published Date: 3/12/2026
Notice
Summary
The FDA is officially pulling the plug on 15 drug approvals because the companies, including Watson Laboratories and others, told the FDA they stopped selling these medicines. This change kicks in on April 13, 2026, but companies can apply again if they want. No money penalties here—just a cleanup to keep things current and clear!
Analyzed Economic Effects
2 provisions identified: 1 benefits, 1 costs, 0 mixed.
Fifteen Generic Drug Approvals Withdrawn
The FDA is withdrawing approval of 15 abbreviated new drug applications (ANDAs) for listed generic medicines (examples include cimetidine, fluoxetine HCl, famotidine, sotalol HCl, paclitaxel injectable, doxazosin mesylate, gabapentin, bisoprolol fumarate/hydrochlorothiazide, and vinorelbine tartrate) as of April 13, 2026. The applicants told FDA they stopped marketing these products, and products in inventory on April 13, 2026 may still be dispensed until the inventory is depleted or the product expires.
Manufacturers May Refile; No Penalty
The FDA says the withdrawals are "without prejudice to refiling," so applicants may submit new ANDAs again if they choose. The applicants waived their opportunity for a hearing, and the notice describes this action as a cleanup rather than a monetary penalty.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Take It Personal
Get Your Personalized Policy View
Start a Free Government Policy Watch to see how policy affects your household, then upgrade to PRIA Full Coverage for year-round monitoring.
Already have an account? Sign in